Virginia Commonwealth University

VCU Scholars Compass
Theses and Dissertations

Graduate School

2009

Heritability of Autoantibody Levels in a Twin Population
Amal Rastogi
Virginia Commonwealth University

Follow this and additional works at: https://scholarscompass.vcu.edu/etd
Part of the Periodontics and Periodontology Commons
© The Author

Downloaded from
https://scholarscompass.vcu.edu/etd/1854

This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has
been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass.
For more information, please contact libcompass@vcu.edu.

School of Dentistry
Virginia Commonwealth University

This is to certify that the thesis prepared by Amal Rastogi, DMD, PhD entitled
HERITABILITY OF AUTOANTIBODY LEVELS IN A TWIN POPULATION
has been approved by his committee as satisfactory completion of the thesis requirement
for the degree of Master of Science in Dentistry.

John Gunsolley, DDS, MS, Professor, Department of Periodontics, VCU, School of Dentistry

Harvey Schenkein, DDS, PhD, Chair, Department of Periodontics, VCU, School of Dentistry

Robert Sabatini, DDS, MS, Assistant Professor, Department of Periodontics, VCU, School of Dentistry

Thomas Waldrop, DDS, MS, Graduate Director, Department of Periodontics, VCU, School of Dentistry

Harvey Schenkein, DDS, PhD, Chair, Department of Periodontics, VCU, School of Dentistry

Laurie Carter, DDS, PhD, Director of Advanced Dental Education,VCU, School of Dentistry

Dr. F. Douglas Boudinot, Dean of the Graduate School, VCU

June 29, 2009

© Amal Rastogi, DMD, PhD 2009
All Rights Reserved

2

HERITABILITY OF AUTOANTIBODY LEVELS IN A TWIN POPULATION
A thesis submitted in partial fulfillment of the requirements for the degree of MSD at
Virginia Commonwealth University.
by

AMAL RASTOGI

Bachelor of Science, Oklahoma State University, 1998
Master of Science, Oklahoma State University, 2000
Doctor of Dental Medicine, Medical University of South Carolina, 2007
Doctor of Philosophy, Medical University of South Carolina, 2007

Director: JOHN C GUNSOLLEY, DDS, MS
PROFESSOR, DEPARTMENTOF PERIODONTICS

Virginia Commonwealth University
Richmond, Virginia
August, 2009

4

Table of Contents
Page
List of Tables ..................................................................................................................... 2
List of Figures ..................................................................................................................... 3
Chapter
1

CHAPTER 1 INTRODUCTION....................................................................... 6

2

CHAPTER 2 METHODS ............................................................................... 14

3

CHAPTER 3 RESULTS ................................................................................. 18

4

CHAPTER 4 DISCUSSION ........................................................................... 29

5

CHAPTER 5 CONCLUSION ......................................................................... 35

References ......................................................................................................................... 37

1

List of Tables
Page
Table 1: Descriptive Statistics. .......................................................................................... 24
Table 2: Intraclass Correlation Coefficients for Continuous Antibody Values. ............... 25
Table 3: Intraclass Correlation Coefficients for Ranked Autoantibody Values. ............... 25
Table 4: Path Models for Continuous Antibody Values. .................................................. 26
Table 5: Heritability Estimates of Continuous Antibody Values. ..................................... 26
Table 6: Path Models for Ranked Autoantibody Values. .................................................. 27
Table 7: Heritability Estimates of Ranked Autoantibody Values. .................................... 27

2

List of Figures
Page
Figure 1: Concordance Rate by Antibody ......................................................................... 28

3

Abstract

HERITABILITY OF AUTOANTIBODY LEVELS IN A TWIN POPULATION
By AMAL RASTOGI, DMD, PHD
A thesis submitted in partial fulfillment of the requirements for the degree of Master of
Science in Dentistry at Virginia Commonwealth University.

Virginia Commonwealth University, 2009

Major Director: John C. Gunsolley, DDS, MS
Professor, Department of Periodontics

AIM: This study aims to determine what portion of specific autoantibody
phenotypes are genetically determined by using a twin model. METHODS: This study
specifically examines Anti-Ro(SSA), Anti-La (SSB), Anti-Sn/RNP, Anti-Sm, Anti-Jo-1,
Anti-Scl-70, Anti-Tg & Anti-TPO, Anti-dsDNA, Anti-PS, and Anti-cardiolipin antibodies
for their heritability. This study examined 104 same-sex adult twins (66 monozygous, 38
dizygous) for the above mentioned autoantibody values. The serum autoantibody values in
each subject were quantified using automated ELISA. Descriptive statistics including,
distributions, quantiles, and moments were calculated by zygosity for continuous antibody
values, subject ages, gender, race and smoking status. Categorical antibody levels were
4

used to determine twin pair concordance rates. Continuous and rank ordered autoantibody
values were used to determine the presence and portion of a genetic component. To
evaluate how strongly the antibody values in each twin group resembled each other, the
intraclass correlation was calculated for each antibody by zygosity. The genetic variances,
environmental variances, and heritability were estimated using path models with maximum
likelihood estimation techniques. The phenotypic variance was modeled as a linear
function of underlying additive genetic (A), dominant genetic (D), common environmental
(C), and random environmental (E) effects. RESULTS: Several antibodies demonstrated
a genetic component in our study population. Anti-cardiolipin had a genetic component
with an estimated 69% heritability. Anti-dsDNA yielded a genetic component with a
heritability estimate of 55-62%. Anti-Jo-1 presented a genetic component with the
heritability estimate to be 41-51%. Anti-SCL-70 demonstrated a genetic component with a
heritability estimate of 42-59%. Anti-PL had a genetic component with a heritability
estimate of 52-54%. Several antibodies did not have a measurable genetic component.
These included anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO.
Some possibilities for the lack of a measureable genetic component may be due to the
limited number of discordant twin pairs and/or the small number of subjects with higher
levels of antibodies. CONCLUSION: The results of this study suggest several clinically
relevant markers of auto-immunity may be partially genetically determined. These include:
anti-cardiolipin, anti-dsDNA, anti-Jo-1, anti-SCL-70, and anti-phospholid.
This document was created in Microsoft Word 2003 SP3.
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CHAPTER 1

INTRODUCTION

Autoimmunity is the failure of an organism to recognize its own constituent parts
as self, which results in an immune response against its own cells and tissues. Numerous
diseases result from such an aberrant immune response. Prominent examples include
Celiac disease, diabetes mellitus type 1 (IDDM), systemic lupus erythematosus (SLE),
Sjögren's syndrome, Churg-Strauss Syndrome, Hashimoto's thyroiditis, Graves' disease,
idiopathic thrombocytopenic purpura, and rheumatoid arthritis.
Most autoimmune diseases have evidence of a genetic and environmental
component. Studies have found familial aggregation of autoimmune diseases such as SLE
and rheumatoid arthritis. An analysis of a cohort of 1,177 SLE patients found an increased
prevalence of SLE and rheumatoid arthritis in siblings1. They also found an increased
familial aggregation of autoimmune diseases in this SLE cohort. Other diseases with
evidence of a strong genetic component include autoimmune thyroid diseases. Twin
studies and familial aggregation indicate that autoimmune thyroid diseases have a complex
genetic component. These studies implicate major histocompatability complex and the
single nucleotide polymorphism Fc receptor-like 3 as genetic factors2.
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Some autoimmune diseases do not have strong evidence for a specific genetic
component. An example includes Sjögren's syndrome. The prevalence of primary
Sjögren's syndrome in siblings of affected individuals has been estimated to be 0.09%
while the reported general prevalence of the disease is approximately 0.1%3. However,
there has been an observed aggregation of other autoimmune diseases in families of
patients with Sjögren's syndrome.
For the majority of these diseases and their specific markers, it is not clear what
portion is heritable. Understanding the genetic and environmental component of
autoimmune markers is the first step in developing novel treatments for autoimmune
diseases. This study examines what portion of specific autoimmune markers are
genetically determined by using a twin model. The subject sample utilized in this study is
an existing set of monozygous and dizygous twins with cross sectional assays of
autoantibodies. This unique population of twins was originally recruited as part of another
study examining genetic risk for periodontal disease4. The assays conducted included antinuclear, anti-thyroid, and anti-phospholipid antibodies with diagnostic or clinical
relevance.

Anti-Nuclear antibodies
Anti-Ro(SSA), Anti-La (SSB), Anti-Sn/RNP, Anti-Sm, Anti-dsDNA, Anti-Jo-1, Anti-Scl-70

Several unique autoantibodies are associated with autoimmune diseases and are
frequently used as serological markers for diagnosis and monitoring. A common
7

serological indicator of autoimmunity in rheumatic disease is the Ro(SSA) antigen5. Over
half of patients with Sjögren's syndrome (SS), one-third of patients with systemic lupus
erythematosus (SLE), and 3-5% of patients with rheumatoid arthritis (RA) have antibodies
to Ro(SSA). Other diseases which have been associated with these antibodies include:
Sjögren's syndrome-lupus overlap disease, subacute cutaneous lupus erythematosus, lupus
with complement component deficiencies, neonatal lupus syndrome, multiple myeloma,
polymyositis, progressive systemic sclerosis and primary biliary cirrhosis6. Anti-Ro(SSA)
antibodies are also found in healthy women of reproductive age with an incidence of 1%7,
8

. Anti-La(SSB) antibodies are typically found in conjunction with anti-Ro(SSA)9, 10.

Small RNA molecules called hy-RNAs are the target protein antigens of anti-Ro(SSA)11.
Complexes of the anti-RO(SSA) with hy-RNAs are termed Ro-ribonucleoproteins (RoRNPs) exist but it is not yet clear what their biological function is12. Both anti-Ro/SSA
and anti-La/SSB antibodies are directed against extractable nuclear antigens.
Another group of nuclear proteins, known as the Sm proteins, were first discovered
as antigens targeted by anti-Sm antibodies in a patient with SLE. Other proteins with very
similar structures were subsequently discovered and named LSm proteins. New members
of the LSm protein family continue to be identified and reported. The Sm autoantigens,
named after patient Smith’s prototype serum, were isolated in the 1960’s by
immunodiffusion13. As in the case with autoimmune syndrome, anti-Sm antibodies are
often found concurrent with other autoantibodies, including, SSA(Ro), SSB(La), DNA,
histone, and RNP. Anti-Sm is, however, a highly specific marker for SLE since there is a
25% prevalence of anti-Sm in SLE patients14.
8

Sm autoantigen is a class of antibodies against the group of nuclear Sm antigens.
There are currently nine unique proteins which are classified as Sm antigens. These nine
polypeptides comprise the core proteins of small nuclear ribonucleoprotein (snRNP)
particles. The typical biological function of SnRNPs is involvement in pre-mRNAsplicing15. Anti-Sm antibodies bind to a broad variety of snRNAs16. This is due to the fact
that they interact with proteins common to different subunits of snRNP particles (B, D, E,
F and G subunits). The D subunit reacts to the majority of Sm autoantigen, however
several of the subunits share at least one epitope. An explanation for the immunologic
cross-reactivity of Sm proteins is the evolutionarily conserved structural sequence motifs.
Sequence comparison has shown that all of the known Sm proteins share two
evolutionarily conserved structural sequence motifs17.
The snRNP particles are also known to elicit an autoantibody response in certain
individuals. Anti-sn/RNP antibodies were first observed in SLE patients16. Later, antisn/RNP antibodies were also associated with mixed connective tissue disease (MCTD)
patients. Studies have found that high levels of anti-sn/RNP in the absence of Sm to be a
reliable marker for MCTD18. Anti-sn/RNP also occurs in other rheumatic diseases such as
progressive systemic sclerosis, rheumatoid arthritis, discoid lupus erythematosus, Sjögren's
syndrome, and overlapping conditions.
Another potential antigenic component in the nucleus is DNA itself. In some
circumstances, double stranded DNA can create an autoimmune response. Anti-double
stranded DNA (Anti-dsDNA) is an IgG or IgM anti-double stranded DNA antibody that
binds to nuclei or nuclear components. Anti-dsDNA is associated with several conditions
9

including, systemic lupus erythematosus (SLE), rheumatoid arthritis, mixed connetictive
tissue disease, Sjögren's syndrome, and necrotizing vasculitis. Serum anti-dsDNA levels
correlate with SLE disease activity and are highly specific to SLE19. High levels are
associated with kidney and blood vessel damage.
The tRNA synthetase group of enzymes is another target for anti-nuclear
antibodies. The histidyl-tRNA synthetase (HRS) enzyme is the target for anti-Jo-1. The
HRS enzyme catalyses the following chemical reaction.

ATP + L-histidine + tRNAHis

AMP + diphosphate + L-histidyl-tRNAHis

HRS specifically catalyses the coupling of L-histidine to tRNAHis before transport to the
ribosome20. At the ribosome, L-histidyl-tRNAHis is incorporated into a polypeptide chain
during protein synthesis. Anti-Jo-1 is the most common autoantibody in polymyositosis
(PM) and dermatomyositis (DM)21. PM and DM are inflammatory myopathies with
proximal muscle weakness, and elevated muscle enzyme activities. PM and DM patients
have a reported an auto-antibody prevalence rate up to 89%, indicating a likely
autoimmune pathology21. The specific prevalence rate for anti-Jo-1 is 15-20% of
myositosis patients and about 30% of adult PM patients22. Anti-Jo-1 antibodies are
capable of inhibiting HRS activity, may immunoprecipitate labeled enzyme, and may
precipitate tRNAhis23.
Another anti-nuclear antibody is the anti Scl-70. The antigen of Anti Scl-70 was
recognized as topoisomerase I in 198624. Topoisomerase I assists in DNA reproduction,
by cutting one strand of a DNA double helix, allowing relaxation, and subsequent
10

reannealing of the cut strand. Topoisomerase I solves the problem caused by tension
generated by the winding/unwinding of DNA25. Anti Scl-70 is recognized as one of two
major classes of autoantibodies in scleroderma. Scleroderma, also known as progressive
systemic sclerosis, is a chronic autoimmune disease characterized by a hardening or
sclerosis in the skin or other organs26. Scleroderma’s clinical manifestations include
collagen deposition leading to connective tissue destruction of the skin, blood vessels, and
some internal organs. A study has estimated the prevalence of scleroderma to be 1 per
500027. The prevalence of anti-Scl-70 in scleroderma patients is approximately 25%28.
Those scleroderma patients with more skin lesions tend to have the highest rates of AntiScl-70 antibodies in their sera29.

Anti-Thyroid antibodies
Anti-Tg & Anti-TPO

Detection of autoantibodies to the two major thyroid antigens thyroglobulin (Tg)
and thyroid peroxidase (TPO) is valuable in the diagnosis of patients with thyroid disease.
Over 98% of thyroiditis patients have autoantibodies directed to either or both of these
antigens.
The presence of anti-Tg autoantibodies has been shown to be a strong indicator of
chronic autoimmune thyroid diseases such as Hoshimoto's thyroiditis and Graves disease30,
31

. While many patients elaborate antibodies to both thyroid antigens, several cases have

been shown to be anti-Tg positive and anti-TPO negative, or vice versa. Therefore,
11

combined determination of both anti-Tg and anti-TPO antibodies provides the most
accurate diagnostic tool for thyroid autoimmunity.

Anti-Phospholipid antibodies
Anti-PS & anti-cardiolipin

Anti-phospholipid antibodies are antibodies against specific phospholipids found in
cell membranes32. Anti-phospholipid antibodies react against proteins that bind to anionic
phospholipids on plasma membranes. Anti-phospholipid antibodies are associated with
primary and secondary antiphospholipid syndromes. Primary antiphospholipid syndrome
is a disorder of coagulation, that may cause thrombosis, miscarriage, preterm delivery, and
severe pre-eclampsia. Secondary antiphospholipid syndrome occurs with other autoimmune diseases such as SLE. Anti-phosphatidylserine antibody (Anti-PS) is a common
antibody associated with both antiphospholipid syndromes33.
A specific antiphosholipid antibody is anti-cardiolipin. Cardiolipin is a
mitochondrial membrane phospholipid. Anti-cardiolipin is associated with
antiphospholipid syndrome, livedoid vasculitis, myocardial infarction, Behçet's syndrome,
SLE, rheumatoid arthritis, and scleroderma34-36. Anti-cardiolipin has been associated with
cardiovascular sequelae such as atherosclerosis and stroke37. Anti-cardiolipin has been
linked to adverse pregnancy outcomes such as idiopathic spontaneous abortion, fetal
involution, prematurity, and low birth weight38. Antibodies to cardiolipin require a cofactor called -2-glycoprotein I for binding39.
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-2-glycoprotein I is a phospholipid-

binding protein that functions as a anticoagulant40. Studies suggest that bound -2glycoprotein I forms the antigen to which antibodies are directed. It is also hypothesized
that the anti-cardiolipin and -2-glycoprotein I complex may have several inhibitory
effects on the coagulation pathway and platelet aggregation39.
This study aims to determine what portion of specific autoantibody phenotypes are
genetically determined by using a twin model. This study specifically examines AntiRo(SSA) antibodies, Anti-La (SSB) antibodies, Anti-Sn/RNP, Anti-Sm antibodies, AntiJo-1 antibody, Anti-Scl-70 antibody, Anti-Tg & Anti-TPO antibodies, Anti-dsDNA
antibody, Anti-PS antibodies, and Anti-cardiolipin antibodies for their heritability.
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CHAPTER 2

METHODS

Sample Population & Examination Protocol
This cohort included one-hundred four (104) same-sex adult twin pairs that were
originally part of a study examining periodontal disease and autoimmunity. The subjects
were recruited from the Virginia twin registry. The registry contained the names of over
20,000 twins born in Virginia between 1915 and 1975. Informed consent was obtained
from all subjects with approval from the Virginia Commonwealth University’s
Institutional Review Board. The zygosity of all twins was classified using a biographical
questionnaire designed to assess physical similarities during youth41.

Assays of antibodies
All subjects had one blood sample taken and processed for serum, which was then
stored at -20°C until utilized. Automated cross sectional enzyme linked immuno-sorbent
assays (ELISA) of cotinine and autoantibodies were conducted on these serum samples.
Serum samples were assayed by Dyn-BioShaf, LTD, Tel Hannan, Israel. The antibodies
assayed included the following:

Anti-Ro(SSA) antibodies (IgG)
14

Anti-La SSB antibodies (IgG)
Anti-Sn/RNP (IgG)
Anti-Sm antibodies (IgG)
Anti-Jo-1 antibody (IgG)
Anti-Scl-70 antibody (IgG)
Anti-Tg & Anti-TPO antibodies (IgG, IgM, IgA)
Anti-dsDNA antibody (IgG)
Anti-PS antibodies (IgG, IgM, IgA)
Anti-cardiolipin antibody (IgG, IgM, IgA)

Statistical Methods
Descriptive statistics including distributions, quantiles, and moments were
calculated by zygosity for continuous antibody values, subject ages, gender, race and
smoking status. The antibody data was categorized as high or low by comparing to
standard curves established with 100 healthy subjects. The categorical antibody data was
used to calculate percent concordance for each twin pair. Descriptive statistics and
concordance were calculated using statistical analysis (JMP® Statistical Discovery
Software Ver 8.0) and spreadsheet software (Microsoft Office Excel ® 2003).
The one-way random effects model was used to calculate intraclass correlations
with 95% confidence intervals for each antibody by zygosity. Due to the distribution of
the auto-antibody values, the values were adjusted by ranking from lowest to highest. The
ranked antibody values also had intraclass correlation coefficients calculated by zygosity.
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Intraclass correlations adjusted by significant covariates were additionally determined.
Significant covariates used for adjusting intraclass correlations were selected by using a
multivariate step-wise regression technique. Intraclass correlations were calculated using
statistical analysis software (PASW Statistics Ver 17.0).
In order to determine what portion of specific autoantibody phenotype is
genetically determined, genetic variances, environmental variances, and heritability was
estimated using path models with maximum likelihood estimation techniques. The
phenotypic variance was modeled as a linear function of underlying additive genetic (A),
dominant genetic (D), common environmental (C), and random environmental (E) effects.
Univariate path models coupled with maximum likelihood estimation coefficient models
were used to estimate these parameters for each antibody. Both antibody values and
antibody rank values were analyzed using path modeling. Variance/covariance matrices
were used with the structural equation modeling methods contained in an on-line module
(http://statgen.iop.kcl.ac.uk/bgim/twinfit.html) and with Windows Mx GUI (Version 1.54a,
Virginia Commonwealth University, Richmond, Virginia) to estimate model parameters
using maximum likelihood techniques. The fit of the model was evaluated from log
likelihood computations with an alpha of 0.05. The full ADCE model could not be tested
since D and C are confounded when data are available only from reared together twins.
The fits of reduced models were compared to the full model (e.g., ACE or ADE) by
inspecting changes in -2*log likelihood values relative to differences in the degrees of
freedom between models42. The module returned the maximum-likelihood estimates for
the ACE, ADE, nested sub-models, determined the best-fitting, most parsimonious model,
16

and gave standardized estimates of the model parameters. A statistically significant
estimate of the A or D parameter signified the presence of significant broad sense
heritability. Broad sense heritability estimates for each antibody were calculated as the
ratio of genetic variance to total variance.
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CHAPTER 3

RESULTS

This study examined a monozygous-dizygous twin population to evaluate the
heritability of eleven autoantibodies. Autoantibodies were measured once in the serum of
the study population. The level of autoantibodies was quantified using ELISA. The
distribution of each of the eleven antibodies proved to be skewed (Table 1). The majority
of subjects tended to have minimal values and a few subjects exhibited higher values,
however, there were not enough subjects with higher values to show a true bimodal
distribution. The autoantibody values were examined three ways, categorically,
continuously, and by ranking the continuous values. The categorical antibody values were
used to determine concordance rates between twin pairs. The continuous and ranked
antibody values were examined using intraclass correlations and ADCE path modeling.
These multiple analysis methods were chosen in order to correct for the skewed
distributions and to thoroughly evaluate the antibody values for evidence of heritability.
Descriptive statistics are shown in Table 1. Monozygous and dizygous groups
were evaluated for statistically significant differences at an α < 0.05 with χ2 testing on
gender, smoking, and racial data. Student’s t test (α < 0.05) was used to evaluate
statistically significant differences for age and autoantibody values. The monozygous
(n=66) and dizygous (n=38) twins were statistically similar in age and percent of smokers.
The mean ages were 44 and 47 years for the monozygous and dizyogous twins
respectively. The percentage of current smokers was 30% for the monozygous group and
18

26% for the dizygous group. The monozygous twins were more likely to be African
American and female, however, these differences were not statistically significant. There
were 20% more females and 8% more African Americans in the monozygous group. The
mean values, standard deviation, minimum, maximum, and median for each autoantibody
are presented in Table 1. The autoantibody means were not significantly different between
the monozygous and dizygous groups.
Categorical analysis provided a method to compare the subjects with higher values
to those with lower values. The antibody values were categorized as high or low by
comparison to standard curves. The categorized values were used to determine
concordance between twin pairs (Figure 1). The monzygous twin pair concordance was
compared to the dizygous twin pair concordance for each of the 11 antibodies. There were
no significant differences between the concordance of monzygous versus dizygous twin
pairs for any of the 11 antibodies evaluated. The categorical method minimizes variance in
the data, but at a cost of statistical power. There were not enough subjects to detect a
significant difference in categorical conocordance rates. Categorizing the auto-antibody
values as high or low is also dependent on the cut-off point selected for high values.
In order to determine how strongly the antibody values in each twin group
resembled each other, the intraclass correlation coefficients were calculated. The intraclass
correlation coefficients and 95% confidence intervals are presented in Table 2 for each
antibody by twin group. To provide the greatest power to detect evidence of heritability,
the continuous autoantibody values were examined. Higher correlation coefficients
represent greater similarities within the twin group. The intraclass correlation coefficients
19

were compared between the monzygous and dizygous twin groups to determine evidence
of a genetic effect. If there is a significant genetic component to an autoantibody value,
one would expect the monozygous intraclass correlation coefficient to be greater than that
of the dizygous group. Anti-SCL-70 and anti-PS antibodies had significant differences (α
< 0.05) in their intraclass correlation coefficients between the monozygous and dizygous
groups. Both anti-SCL-70 and anti-PS antibodies had a greater intraclass correlation
coefficient in the monozygous group. Examining intraclass-correlation in the continuous
data of our study population finds anti-SCL-70 and anti-PS antibodies to potentially have a
genetic component. Table 2 includes both the unadjusted and adjusted intraclass
correlation coefficients. Smoking status, race, gender, and age were evaluated for
significant confounding using stepwise regression. Race, gender, and age did not prove to
be significant confounders for any antibody. Only anti-cardiolipin and anti-SCL-70 values
were significantly related to smoking.
The options to examine data that has a skewed distribution include categorizing,
excluding outliers, adjustment (i.e. logarithmic or exponential), or ranking. A decision was
made to rank the antibody values in order to maintain the full distribution of the data but
minimizing the range and variance. Antibody values were ranked from the lowest to
highest for each twin group. The intraclass correlation was calculated for each antibody
(Table 3). The intraclass correlation coefficients and 95% confidence intervals are
presented in Table 3 for each antibody by twin group. Table 3 includes both the
unadjusted and adjusted intraclass correlation coefficients. Smoking status, race, gender,
and age were evaluated for significant confounding using stepwise regression. Race,
20

gender, and age did not prove to be significant confounders for any antibody. As with the
non-ranked values, only anti-cardiolipin and anti-SCL-70 values were confounded by
smoking. Also similar to the non- ranked values, only anti-SCL-70 and Anti-PS antibodies
had significant differences (α < 0.05) in their intraclass correlation coefficients between the
monozygous and dizygous groups. Both anti-SCL-70 and anti-PS antibodies had a greater
intraclass correlation coefficient in the monozygous group. All intraclass correlation
coefficients were equal to or greater than those found using continuous autoantibody
values. This was to be expected, since the ranked values were more closely correlated than
the continuous values. Examining intraclass correlation in the ranked data of our study
population found anti-cardiolipin, anti-dsDNA, anti-SCL-70, and anti-PS antibodies to
potentially have a genetic component. When both the continuous and ranked intraclass
correlation were taken into consideration, anti-SCL-70 and anti-PS antibodies were the
most likely to have a genetic component.
In order to determine what portion of specific autoantibody phenotype is
genetically determined, genetic and environmental variances, and heritability were
estimated using path models with maximum likelihood estimation techniques. Path
models coupled with maximum likelihood estimation methods have an advantage over
conventional ANOVA methods in that the fit of full and reduced models can be evaluated
and compared using the data43. There are several basic assumptions of path model fitting
to twin data. The variances in the monzygous and dizygous groups must be approximately
equal. If they are not, a poor fit or a failure of convergence will result42. The covariances
must be less than the variances, which is a basic property of all properly-constructed
21

covariance matrices. The dizygous covariance must be less than the MZ covariance which
is an implication of the genetic model. The ACE model will never fit well if this is not
true, although it is possible to observe this given the nature of random sampling. Some
antibodies violated the basic assumptions of the path model, and were noted as nonconvergent.
The results of the convergent path models using continuous antibody values are
shown in Table 4. Table 4 presents the most parsimonious model and parameter estimates
for each antibody. The most parsimonious model for anti-cardiolipin as well as anti-TPO
was CE, indicating no genetic component. The most parsimonious model for anti-dsDNA
and anti-SCL-70 was AE, indicating an additive genetic component. The most
parsimonious model for anti-Jo-1 and anti-PS was DE, indicating a dominant genetic
component.
The ratio of genetic variance to total variance (broad sense heritability) was
calculated from the path models and presented in Table 5. The broad sense heritability is
more meaningful then the narrow sense additive or dominant genetic effects, since the
power was insufficient to distinguish between broad sense and narrow sense heritability.
Table 5 lists the heritability estimates for the most parsimonious model, the full ACE
model, and the full ADE models. The heritability estimate was 55% for anti-dsDNA, 41%
for anti-Jo-1, 42% for anti-SCL-70, and 52% for anti-PS.
Heritability was estimated using path models on the ranked antibody data as well.
The results of the convergent path models using antibody value ranking are shown in Table
6. Table 6 presents the most parsimonious model and parameter estimates for each
22

antibody. The most parsimonious model for anti-Sm, anti-Ro(SSA), and anti-n-RNP was
CE, indicating no genetic component. The most parsimonious model for anti-cardiolipin,
anti-dsDNA, anti-Jo-1, and anti-SCL-70 was AE, indicating an additive genetic
component. The most parsimonious model for anti-PS was DE, indicating a dominant
genetic component.
Table 7 lists the heritability estimates using the ranked antibody values for the most
parsimonious model, the full ACE model, and the full ADE models. The heritability
estimate was 69% for anti-cardiolipin, 62% for anti-dsDNA, 51% for anti-Jo-1, 59% for
anti-SCL-70, and 54% for anti-PS.
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TABLE 1 Descriptive Statistics
Age (years)
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
Sn/RNP
SCL-70
PS
Tg
TPO
Female
Current Smokers
African American

MZ (n=66)
Mean
43.7
18.7
28.3
10.9
17.7
33.0
20.4
16.4
9.5
17.9
25.4
24.9
Number
50
20
16

SD
3.9
25.8
28.6
11.3
18.6
149.0
78.6
32.7
9.3
14.2
20.9
76.0
%
67%
30%
24%

Minimum
39.1
0.0
2.5
2.3
1.7
1.3
1.2
0.7
2.2
0.7
10.2
1.0

Maximum
52.9
156.5
176.8
73.6
87.6
1209.0
642.4
255.7
55.8
69.8
151.6
517.4
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Median
42.5
9.8
21.6
7.2
11.9
7.6
6.2
8.1
6.3
14.2
19.0
3.3

DZ (n=38)
Mean
46.6
13.6
26.6
9.3
13.2
15.5
10.1
8.7
8.2
20.3
32.7
33.9
Number
18
10
6

SD
4.5
12.1
18.3
9.5
14.2
16.6
18.1
9.1
6.2
18.7
32.6
93.9
%
47%
26%
16%

Minimum Maximum Median
38.7
55.3
47.0
0.4
51.2
9.3
4.4
87.4
22.5
1.9
60.4
6.9
0.6
84.9
10.2
0.7
59.0
5.1
0.9
107.4
5.1
0.5
37.4
4.5
1.8
23.9
5.5
2.8
86.7
15.1
8.6
198.3
22.6
1.1
416.5
4.5

TABLE 2 Intraclass Correlation Coefficients
antibody
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
Sn/RNP
SCL-70
PS
Tg
TPO
Cardiolipin
SCL-70

ICC (95% CI)
MZ
lower bound upper bound
0.663
0.422
0.818
0.495
0.191
0.713
0.424
0.103
0.666
0.321
-0.016
0.594
0.004
-0.332
0.341
-0.015
-0.349
0.324
0.144
-0.202
0.459
0.312
-0.026
0.587
0.535
0.243
0.739
-0.038
-0.368
0.303
0.611
0.347
0.786
0.660
0.426
0.805
-0.014
0.558
0.294

DZ
lower bound upper bound
0.562
0.167
0.804
0.413
-0.028
0.722
-0.002
-0.438
0.439
0.519
0.107
0.781
0.105
-0.347
0.522
0.046
-0.398
0.477
0.368
-0.081
0.696
0.251
-0.208
0.623
0.002
-0.434
0.443
-0.002
-0.438
0.439
0.555
0.157
0.800
0.671
0.257
0.844
-0.328
-0.688
0.114

adjusted for
smoking
smoking

TABLE 3 Intraclass Correlation Coefficients for Ranked Autoantibody Values
antibody
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
SnRNP
SCL-70
PS
Tg
TPO
Cardiolipin
SCL-70

ICC (95% CI)
MZ
lower bound upper bound
0.688
0.458
0.832
0.608
0.342
0.784
0.505
0.204
0.719
0.676
0.440
0.825
0.458
0.144
0.689
0.390
0.063
0.643
0.714
0.498
0.847
0.566
0.285
0.759
0.546
0.258
0.746
0.294
-0.046
0.575
0.716
0.501
0.848
0.683
0.456
0.830
0.562
0.284
0.758
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DZ
lower bound upper bound adjusted for
0.409
-0.032
0.720
0.371
-0.078
0.698
0.324
-0.130
0.669
0.594
0.214
0.820
0.443
0.009
0.739
0.456
0.026
0.747
0.657
0.310
0.851
0.341
-0.112
0.679
0.047
-0.397
0.478
0.364
-0.086
0.693
0.722
0.418
0.882
0.540
0.026
0.782 smoking
0.242
-0.161
0.622 smoking

TABLE 4 Path Models for Continuous Antibody Values
Antibody
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
Sn/RNP
SCL-70
PS
Tg
TPO

Model
CE
AE
DE
non-convergent
non-convergent
non-convergent
non-convergent
AE
DE
non-convergent
CE

A

D

C
0.67

0.41

E
0.33
0.44
0.59

-2log likelihood
2.53
0.77
0.46

df
4
4
4

p value
0.28
0.68
0.79

0.52

0.58
0.48

0.01
0.78

4
4

0.99
0.68

0.39

1.27

4

0.53

0.55

0.42

0.61

TABLE 5
Heritability Estimates of Continuous Antibody Values
Outcome
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
Sn/RNP
SCL-70
PS
Tg
TPO

Most Parsimonious Model
0%
55%
41%

full ACE
30%
29%
38%

full ADE
72%
55%
41%

42%
52%

38%
50%

42%
52%

0%

25%

66%
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TABLE 6 Path Models for Ranked Autoantibody Values
Antibody
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
Sn/RNP
SCL-70
PS
Tg
TPO

Model
AE
AE
AE
CE
CE
non-convergent
CE
AE
DE
non-convergent
non-convergent

A
0.68
0.61
0.51

D

C

0.64
0.44
0.69
0.59
0.54

E
0.31
0.38
0.49
0.36
0.56

-2log likelihood df
4
0.60
0.08
4
4
0.22
0.72
4
4
0.03

0.31
0.41
0.47

0.42
0.05
0.51

TABLE 7
Heritability Estimates of Ranked Autoantibody Values
Outcome
Cardiolipin
dsDNA
Jo-1
Sm
Ro(SSA)
La(SSB)
SnRNP
SCL-70
PS
Tg
TPO

Most Parsimonious Model
69%
61%
51%
0%
0%

full ACE
48%
53%
36%
18%
5%

full ADE
68%
61%
51%
67%
48%

0%
59%
54%

12%
52%
51%

69%
59%
54%
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4
4
4

p value
0.74
0.96
0.90
0.70
0.98
0.81
0.98
0.77

FIGURE 1
Concordance Rates by Antibody
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CHAPTER 4

DISCUSSION

This study investigated the heritability of eleven autoantibodies. Five antibodies
demonstrated a genetic component in our study population of monozygous and dizygous
twin pairs. Heritability estimates were 69% for anti-cardiolipin, 55-62% for anti-dsDNA,
41-51% for anti-Jo-1, 42-59% for anti-SCL-70, and 52-54% for anti-phospholid.
The most parsimonious path models for anti-cardiolipin using the ranked values
included an additive genetic component. This finding expands on the partial genetic
determination for anti-cardiolipin found in a previous study44. The study by Hunnangkul
et al examined a cohort of families affected by SLE (n=1,037) and found significant
associations in anti-cardiolipin values between siblings. Our study found significant
differences in intraclass correlation differences between monozygous and dizygous twins
for anti-cardiolipin values. This significant difference supports the hypothesis of a genetic
component for anti-cardiolipin values with an estimated heritability for anti-cardiolipin
expression of 69%.
The most parsimonious path model for anti-dsDNA using both continuous and
ranked values included an additive genetic component. Studies examining anti-dsDNA are
mixed. A study examining the genetic contributions to the autoantibody profile in a rabbit
model of SLE found higher levels of anti-dsDNA among some full siblings and the
presence of higher immune responder ancestors in their pedigrees 45. Puliyath et al’s
findings suggest an additive mode of inheritance with high heritability. However, Niewold
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et al, found anti-dsDNA to be associated with high interferon alpha levels in SLE patients,
interferon alpha to be a complex heritable trait, and anti-dsDNA to be rare in healthy
family members46. The findings of the present study parallel Puliyath et al’s results by
finding intraclass correlation suggestive of a genetic effect, path models suggesting
additive genetic components, and heritability estimates of 55% and 62% by continuous
and ranked analysis, respectively.
Path modeling of anti-Jo-1 suggested a dominant genetic component using
continuous data and an additive genetic component using categorical data. This study
estimated the broad sense heritability to be 41% and 51% by continuous and ranked
analysis, respectively. Furthermore, the study found intraclass correlation to be suggestive
of a genetic component in the continuous data. O’Hanlon et al determined certain genetic
markers to be associated with anti-Jo-1 antibodies47. Although the literature is limited on
anti-Jo-1 heritability, the O’Hanlon et al study provides evidence that anti-Jo-1 may have a
genetic component. Further studies on anti-Jo-1 heritability should be conducted on other
populations to validate our findings.
Both continuous and ranked values of anti-SCL-70 had similar results. The most
parsimonious path models included an additive genetic component. The broad sense
heritability was 42% and 59%, for continuous and ranked values, respectively.
Additionally, the intraclass correlations suggested a genetic component. The literature
supports the finding in this study of a genetic component of anti-SCL-7048. Takehara et al,
examined anti-nuclear antibodies in the relatives (n=35) of patients (n=21) with systemic
sclerosis. The frequency of anti-nuclear antibodies reported in relatives was 26% and anti30

SCL-70 was detected in the mother of a systemic sclerosis subject. Although the literature
is limited and examines only a small population, it supports our findings of a genetic
component of anti-SCL-70.
The continuous and ranked values of anti-PS had comparable results. The most
parsimonious path models included dominant genetic components. The broad sense
heritability was 52% and 54%, for continuous and ranked values, respectively.
Furthermore, the intraclass correlations suggested a genetic component. The literature
supports the findings of this study by providing evidence of linkage for anti-PS to
chromosome 13q1449.
Several antibodies did not have a measurable genetic component. These included
anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO. Path analysis
of the ranked anti-Sm, anti-Ro(SSA), and anti-sn/RNP values indicated the best fitting
model had no genetic component. The covariance matrices of anti-La(SSB), anti-Tg, and
anti-TPO did not fit the assumptions of the path models and consequently the models were
non-convergent. The anti-Tg values had 100% categorical concordance for both
monozygous and dizygous twins and this lack of discordance minimized the potential for
meaningful analysis. The intraclass correlations for anti-Sm, anti-Ro(SSA), anti-La(SSB),
anti-sn/RNP, anti-Tg, and anti-TPO implied that there is not a genetic component
detectable in our sample.
The literature contains several studies which suggest the possibility of a genetic
component for anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO.
Puliyath et al, in a rabbit model of SLE found genetic contributions to the autoantibody
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profile of anti-Sm45. A study of familial aggregation and linkage analysis of autoantibody
traits in pedigrees for SLE reported evidence for linkage to anti-Sm on chromosome
3q2749. Ferreira et al, found IgM anti-Ro to have a uniquely high degree of heritability in a
study of SLE families50. A study of familial aggregation and linkage analysis of
autoantibody traits in pedigrees for SLE found potential evidence for linkage to antiRo(SSA) or anti-La(SSB) on chromosome 4q34-q3549. Several studies have found nuclear
antibodies to be associated between relatives45, 48. The linkage study by Ramos et al, also
reported evidence that anti-sn/RNP linkage may be associated with chromosome 3q2149.
Complex segregation analysis in a population of Amish families suggested that
transmission of anti-TPO is consistent with a mixed model with a major gene transmitted
in an autosomal dominant pattern51. Outschoorn et al demonstrated that anti-Tg and antiTPO exhibited positive heritability in patients with Graves disease, but not in chronic
lymphocytic or Hashimoto’s thyroiditis patients52, 53 As the literature suggests, anti-Sm,
anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO production are likely
genetically complex traits, however, we did not find a significant genetic component for
any of these antibodies in our twin population.
The differences between findings in the literature and the present study may be due
to the limited number of discordant twin pairs and/or the small number subjects with
higher levels of auto-antibodies. This study was limited primarily by the rarity of elevated
auto-antibody levels in the study population, which resulted in two specific complications.
The first was that the distributions for the antibody values tended to be skewed rather than
bimodal. Since there were relatively few subjects with elevated values, the distribution
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presented as normal with a few outliers, skewing the data to the maximum. If there had
been more subjects with higher antibody values, the outliers would likely have created a
second normal distribution. The options to examine data that exhibited a skewed
distribution include categorizing, excluding outliers, adjustment (i.e. logarithmic or
exponential), or ranking. We chose to rank the antibody values so that we would maintain
the full distribution of the data but minimize the range and variance.
The second complication that arises from a lack of subjects with elevated antibody
values is the inherent lack of statistical power. The lack of power probably led to the
inability to detect the presence of genetic components of several of the antibodies. This is
even more likely for the antibodies which had strong literature support for a genetic
component.
Several of the studies reported in the literature examined linkage and associated
antibodies with certain regions of chromosomes. There is a possible explanation of the
discordant findings between the linkage studies and our results. The linkage studies
examined a diseased population (i.e. SLE) with a potentially rare genetic variation that did
not occur in our population. Without this genetic variation, it may be possible to lose the
genetic component of the autoantibody expression.
Another point to consider is the entitiy being measured. The autoantibody assays
evaluate the presence of autoantibodies, not the likelihood of expressing these antibodies.
A genetic component may predispose an individual to create an auto-antibody, however,
unless we are dealing with a purely genetic effect, expression of these antibodies may not
occur in the absence of an environmental trigger. Since these samples were taken from
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twins at one point in time, we are limited to the environmental effects present at that
moment. It is possible that different phenotypic expressions of antibodies may occur at
various points in time.
A second measurement issue relates to the precision, sensitivity, and specificity of
the ELISA assays used to quantify the autoantibody values. The majority of antibody
values are near zero, leading to the potential of false positives. Tan et al, examined the
precision, sensitivity, and specificities of several commercial enzyme based immunoassays
for the detection of anti-nuclear auto antibodies54. They found the most evident lack of
sensitivity and specificity in the anti-dsDNA and anti-Sm kits. Anti-Ro(SSA), antiRoSSB, anti-SCL-70, anti-Jo-1 kits generally perform well. Several false positives were
observed in sera containing multiple myeloma cryoprecipitates. The replicate precision
had a wide variability between manufacturers. The results of this precision, sensitivity,
and specificity analysis suggests a possible source of variability in the auto-antibody
values and, hence, the entire heritability analysis.
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CHAPTER 5

CONCLUSION

This study aimed to determine what portion of specific autoantibody
phenotypes are genetically determined by using a twin model. This study specifically
examined Anti-Ro(SSA) antibodies, Anti-La (SSB) antibodies, Anti-Sn/RNP, Anti-Sm
antibodies, Anti-Jo-1 antibody, Anti-Scl-70 antibody, Anti-Tg & Anti-TPO antibodies,
Anti-dsDNA antibody, Anti-PS antibodies, and Anti-cardiolipin antibodies for their
heritability.
Several antibodies demonstrated a genetic component in our study population.
Anti-cardiolipin had a genetic component with an estimated 69% heritability. Heritability
estimates were 55-62% for anti-dsDNA, 41-51% for Anti-Jo-1, 42-59% for anti-SCL-70,
and 52-54% for anti-PL.
Several antibodies did not have a measurable genetic component. These included
anti-Sm, anti-Ro(SSA), anti-La(SSB), anti-sn/RNP, anti-Tg, and anti-TPO. Possibilities
for the lack of a measureable genetic component include the limited number of discordant
twin pairs, and/or the small number subjects with higher levels of antibodies.
The results of this study suggest several clinically relevant markers of autoimmunity may be partially genetically determined. These include: anti-cardiolipin, antidsDNA, anti-Jo-1, anti-SCL-70, and anti-PL. These findings provide a basis for
understanding the mechanisms involved in the various autoimmune diseases associated

35

with these autoantibodies. Additionally, the presence of a genetic component provides a
new paradigm for possible therapeutics for autoimmune diseases.

36

Literature Cited

37

Literature Cited

1. Alarcon-Segovia D, Alarcon-Riquelme ME, Cardiel MH, et al. Familial aggregation of
systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in
1,177 lupus patients from the GLADEL cohort. Arthritis Rheum 2005;52(4):1138-1147.
2. Shirasawa S. Susceptibility genes for the development of autoimmune thyroid disease.
Nippon Rinsho 2006;64(12):2208-2214.
3. Anaya JM, Tobon GJ, Vega P, Castiblanco J. Autoimmune disease aggregation in
families with primary Sjogren's syndrome. J Rheumatol 2006;33(11):2227-2234.
4. Schenkein HA, Berry CR, Burmeister JA, et al. Anti-cardiolipin antibodies in sera from
patients with periodontitis. J Dent Res 2003;82(11):919-922.
5. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological
heterogeneity in patients with anticentromere antibodies. J Rheumatol 2005;32(8):14881494.
6. Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity
2005;38(1):55-63.
7. Wang CL, Ooi L, Wang F. Prevalence and clinical significance of antibodies to
ribonucleoproteins in systemic lupus erythematosus in Malaysia. Br J Rheumatol
1996;35(2):129-132.
8. Brucato A, Doria A, Frassi M, et al. Pregnancy outcome in 100 women with
autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus
2002;11(11):716-721.
9. Voulgari PV, Katsimbri P, Alamanos Y, Drosos AA. Gender and age differences in
systemic lupus erythematosus. A study of 489 Greek patients with a review of the
literature. Lupus 2002;11(11):722-729.
10. Yee CS, Hussein H, Skan J, Bowman S, Situnayake D, Gordon C. Association of
damage with autoantibody profile, age, race, sex and disease duration in systemic lupus
erythematosus. Rheumatology (Oxford) 2003;42(2):276-279.
11. Hirokawa K, Takasaki Y, Takeuchi K, Kaneda K, Ikeda K, Hashimoto H. Anti-TS1RNA: characterization of novel antibodies against sequence-specific RNA by random
RNA selection in patients with Sjogren's syndrome. J Rheumatol 2002;29(5):931-937.
12. Rutjes SA, Lund E, van der Heijden A, Grimm C, van Venrooij WJ, Pruijn GJ.
Identification of a novel cis-acting RNA element involved in nuclear export of hY RNAs.
RNA 2001;7(5):741-752.
13. Tan EM, Kunkel HG. Characteristics of a soluble nuclear antigen precipitating with
sera of patients with systemic lupus erythematosus. J Immunol 1966;96(3):464-471.
38

14. Neri R, Tavoni A, Cristofani R, et al. Antinuclear antibody profile in Italian patients
with connective tissue diseases. Lupus 1992;1(4):221-227.
15. Reichow SL, Hamma T, Ferre-D'Amare AR, Varani G. The structure and function of
small nucleolar ribonucleoproteins. Nucleic Acids Res 2007;35(5):1452-1464.
16. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies.
Autoimmunity 2005;38(1):47-54.
17. Scofield DG, Lynch M. Evolutionary diversification of the Sm family of RNAassociated proteins. Mol Biol Evol 2008;25(11):2255-2267.
18. Salmhofer W, Hermann J, Joch M, Kerl H, Graninger W. High serum levels of
antibodies against the recombinant 70 kDa ribonucleoprotein are useful for diagnosing
mixed connective tissue disease. J Eur Acad Dermatol Venereol 2007;21(8):1047-1053.
19. Hilliquin P. Biological markers in inflammatory rheumatic diseases. Cell Mol Biol
(Noisy-le-grand) 1995;41(8):993-1006.
20. Mathews MB, Bernstein RM. Myositis autoantibody inhibits histidyl-tRNA synthetase:
a model for autoimmunity. Nature 1983;304(5922):177-179.
21. Targoff IN. Autoantibodies in polymyositis. Rheum Dis Clin North Am
1992;18(2):455-482.
22. Nishikai M, Ohya K, Kosaka M, Akiya K, Tojo T. Anti-Jo-1 antibodies in
polymyositis or dermatomyositis: evaluation by ELISA using recombinant fusion protein
Jo-1 as antigen. Br J Rheumatol 1998;37(4):357-361.
23. Walker EJ, Tymms KE, Webb J, Jeffrey PD. Improved detection of anti-Jo-1 antibody,
a marker for myositis, using purified histidyl-tRNA synthetase. J Immunol Methods
1987;96(2):149-156.
24. Shero JH, Bordwell B, Rothfield NF, Earnshaw WC. High titers of autoantibodies to
topoisomerase I (Scl-70) in sera from scleroderma patients. Science 1986;231(4739):737740.
25. Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev
Biochem 2001;70:369-413.
26. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med
2009;360(19):1989-2003.
27. Bernatsky S, Joseph L, Pineau CA, Belisle P, Hudson M, Clarke AE. Scleroderma
prevalence: Demographic variations in a population-based sample. Arthritis Rheum
2009;61(3):400-404.
28. Savas N, Dagli U, Ertugrul E, Kuran S, Sahin B. Autoantibody profile in systemic
sclerosis as a marker for esophageal and other organ involvement in Turkish populations.
Dig Dis Sci 2007;52(11):3081-3086.
29. Varga J. Systemic sclerosis: an update. Bull NYU Hosp Jt Dis 2008;66(3):198-202.
30. Nakamura H, Usa T, Motomura M, et al. Prevalence of interrelated autoantibodies in
thyroid diseases and autoimmune disorders. J Endocrinol Invest 2008;31(10):861-865.
31. Pedro AB, Romaldini JH, Americo C, Takei K. Association of circulating antibodies
against double-stranded and single-stranded DNA with thyroid autoantibodies in Graves'
disease and Hashimoto's thyroiditis patients. Exp Clin Endocrinol Diabetes
2006;114(1):35-38.
39

32. Horstman LL, Jy W, Bidot CJ, et al. Antiphospholipid antibodies: paradigm in
transition. J Neuroinflammation 2009;6:3.
33. Pasquali JL, Poindron V, Korganow AS, Martin T. The antiphospholipid syndrome.
Best Pract Res Clin Rheumatol 2008;22(5):831-845.
34. Tringali GR, Julian AJ, Halbert WM. Effect of 2-mercaptoethanol treatment on
anticardiolipin reactivity in sera from syphilitics and false positive reactors. Br J Vener Dis
1969;45(3):202-204.
35. Hull RG, Harris EN, Gharavi AE, et al. Anticardiolipin antibodies: occurrence in
Behcet's syndrome. Ann Rheum Dis 1984;43(5):746-748.
36. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by
radioimmunoassay and association with thrombosis in systemic lupus erythematosus.
Lancet 1983;2(8361):1211-1214.
37. Shovman O, Gilburd B, Barzilai O, Langevitz P, Shoenfeld Y. Novel insights into
associations of antibodies against cardiolipin and beta2-glycoprotein I with clinical
features of antiphospholipid syndrome. Clin Rev Allergy Immunol 2007;32(2):145-152.
38. Carp HJ, Meroni PL, Shoenfeld Y. Autoantibodies as predictors of pregnancy
complications. Rheumatology (Oxford) 2008;47 Suppl 3:iii6-8.
39. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Anti-phospholipid antibodies are
directed against a complex antigen that includes a lipid-binding inhibitor of coagulation:
beta 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87(11):41204124.
40. Kandiah DA, Krilis SA. Beta 2-glycoprotein I. Lupus 1994;3(4):207-212.
41. Magnus P, Berg K, Nance WE. Predicting zygosity in Norwegian twin pairs born
1915-1960. Clin Genet 1983;24(2):103-112.
42. Neale MC. Statistical Modeling. Richmond, VA: Medical College of Virginia; 1997:
43. Christian JC. Testing twin means and estimating genetic variance: basic methodology
for the analysis of quantitative twin data. Acta Genet Med Gemellol (Roma) 1979;28(1):3540.
44. Hunnangkul S, Nitsch D, Rhodes B, et al. Familial clustering of non-nuclear
autoantibodies and C3 and C4 complement components in systemic lupus erythematosus.
Arthritis Rheum 2008;58(4):1116-1124.
45. Puliyath N, Ray S, Milton J, Mage RG. Genetic contributions to the autoantibody
profile in a rabbit model of Systemic Lupus Erythematosus (SLE). Vet Immunol
Immunopathol 2008;125(3-4):251-267.
46. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK. High serum IFN-alpha activity
is a heritable risk factor for systemic lupus erythematosus. Genes Immun 2007;8(6):492502.
47. O'Hanlon TP, Rider LG, Schiffenbauer A, et al. Immunoglobulin gene polymorphisms
are susceptibility factors in clinical and autoantibody subgroups of the idiopathic
inflammatory myopathies. Arthritis Rheum 2008;58(10):3239-3246.
48. Takehara K, Moroi Y, Ishibashi Y. Antinuclear antibodies in the relatives of patients
with systemic sclerosis. Br J Dermatol 1985;112(1):23-33.

40

49. Ramos PS, Kelly JA, Gray-McGuire C, et al. Familial aggregation and linkage analysis
of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes
Immun 2006;7(5):417-432.
50. Ferreira R, Barreto M, Santos E, et al. Heritable factors shape natural human IgM
reactivity to Ro60/SS-A and may predispose for SLE-associated IgG anti-Ro and anti-La
autoantibody production. J Autoimmun 2005;25(2):155-163.
51. Pauls DL, Zakarija M, McKenzie JM, Egeland JA. Complex segregation analysis of
antibodies to thyroid peroxidase in Old Order Amish families. Am J Med Genet
1993;47(3):375-379.
52. Outschoorn IM, Rose NR, Burek CL, Jones TW, Mackay IR, Rowley MJ. Heritability
of levels of autoantibodies using the method of plotting regression of offspring on
midparent (ROMP). Autoimmunity 2005;38(4):325-326.
53. Outschoorn IM, Hoffman WH, Rose NR, Burek CL. Heritability of levels of
autoantibodies to thyroid antigens using the method of plotting regression of offspring on
midparent (ROMP). Autoimmunity 2007;40(5):366-371.
54. Tan EM, Smolen JS, McDougal JS, et al. A critical evaluation of enzyme immunoassay
kits for detection of antinuclear autoantibodies of defined specificities. II. Potential for
quantitation of antibody content. J Rheumatol 2002;29(1):68-74.

41

VITA
Dr. Rastogi, was born on June 2, 1978 in Lucknow, India. He is a naturalized
citizen of the United States of America. Dr. Rastogi’s education includes a Bachelor of
Science majoring in molecular cell biology and economics from Oklahoma State
University, a Master of Science in economics from Oklahoma State University, a Doctor of
Dental Medicine from the Medical University of South Carolina, and a Doctor of
Philosophy in epidemiology from the Medical University of South Carolina. He is the
recipient of numerous honors, scholarships, and awards, including a Dental Scientist
Fellowship from the National Institutes of Health.

42

